retatrutide dosage trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Cagrilintide vs Retatrutide Compared |

Rather than acting as a replacement for nutritious eating or regular physical activity, it is designed to work alongside a balanced lifestyle

Because exenatide is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhea, the use of BYDUREON is not recommended in patients with severe gastrointestinal disease

First, it upregulates growth hormone receptor expression at the tendon-to-bone junction, making tissue more responsive to endogenous growth signals

The NEJM paper directly states: "The heart rate increased with retatrutide treatment in a dose-dependent manner, peaking at 24 weeks, followed by a decline at 36 and 48 weeks